Zoetis | ZTS | Long at $156.94
Zoetis 
ZTS, the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets).
Thus, at $156.94,ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change).
Targets
ZTS, the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets). Thus, at $156.94,
ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change).Targets
- $170.00
- $180.00
- $200.00
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.